MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and ...
As of December 6, 2025, the average one-year price target for Veru is $21.68/share. The forecasts range from a low of $10.10 to a high of $31.50. The average price target represents an increase of 850 ...
MIAMI, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, ...
-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an ...
Veru Inc. updates on its Phase 2b clinical trials, expecting safety data and discussing plans for Phase 3 with the FDA. Veru Inc. reported its financial results for the second quarter of fiscal 2025 ...
A telephonic replay will be available at approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), passcode 7682749, for one week. About Veru Inc. Veru is a ...
MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback